Primary analysis: number of vision deterioration events
| No of vision deterioration events | Group L1 Low dose, monthly schedule (n=204) | Group S1 Standard dose, monthly schedule (n=203) | Group L2 Low dose, bimonthly schedule (n=203) | Group S2 Standard dose, bimonthly schedule (n=202) |
| All eyes | 62/232 (27%) | 61/224 (27%) | 83/223 (37%) | 77/225 (34%) |
| Primary eye | 56/200 (28%) | 56/199 (28%) | 73/201 (36%) | 72/199 (36%) |
| Fellow eye | 6/32 (19%) | 5/25 (20%) | 10/22 (45%) | 5/26 (19%) |
| Unrelated to age related macular degeneration | 0 | 1 (<0.5%) | 1 (<0.5%) | 1 (<0.5%) |
| Retinal pigment epithelium rip | 3 (1%) | 1 (<0.5%) | 1 (<0.5%) | 2 (1%) |
| Development of atrophy | 9 (4%) | 7 (3%) | 11 (5%) | 8 (4%) |
| Other | 4 (2%) | 3 (1%) | 3 (1%) | 5 (2%) |
| Reason for visual deterioration not recorded | 7 (3%) | 9 (4%) | 5 (2%) | 7 (3%) |
All data are n (%) unless otherwise indicated.